{
    "clinical_study": {
        "@rank": "163151", 
        "acronym": "TARHF", 
        "arm_group": [
            {
                "arm_group_label": "Rheohemapheresis", 
                "arm_group_type": "Experimental", 
                "description": "Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. Best-corrected visual acuity, electroretinography and drusenoid retinal pigment epithelium detachment area will be examined. Changes of selected special immunologic parameters will be measured."
            }, 
            {
                "arm_group_label": "without rheohemapheresis", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Into the group the patients will be randomized with the same disease but without rheohemapheresis"
            }
        ], 
        "brief_summary": {
            "textblock": "In this research rheohemapheresis will be used for the treatment of patients with high-risk\n      dry form of age-related macular degeneration. Correction of rheologic parameters and\n      activation of retinal functional reserves after the therapy will positively influence\n      functional condition of retina. The newest special electrophysiologic methods will be used\n      to determine retinal changes in time. The investigators will also evaluate some important\n      immunologic factors and complement changes as well as define indication criteria more\n      precisely."
        }, 
        "brief_title": "Treatment of AMD With Rheohemapheresis /RHF/", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Age Related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "detailed_description": {
            "textblock": "With optimized therapeutic protocol we would prevent progression of the dry form of AMD into\n      its devastating wet form and stabilize the situation. We suppose that retinal morphologic\n      and functional conditions would improve in a high percentage of patients. Also possible\n      technical and economic savings would not be less important with our own therapeutic\n      protocol, especially, when blindness could be prevented."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients with AMD in the stage of soft drusen, grade 1-3 according to European Eye Study\n        (EURYEYE) (see reference No 1), body weight over 50 Kilo and with other feasible\n        indications for aphereses therapy (peripheral veins allowing vascular access to establish\n        the extracorporal circuit).\n\n        -\n\n        Exclusion Criteria:\n\n          -  Study eye with exudative AMD\n\n          -  Study eye with concomitant retinal or choroidal disorder other than AMD\n\n          -  Study eye with significant central lens opacities and/or conditions that limit the\n             view of the fundus\n\n          -  uncontrolled diabetes, uncontrolled arterial hypertension\n\n          -  insufficient antecubital venous access\n\n          -  haemato-oncological malignancies\n\n          -  patients who are unwilling to adhere to visit examination schedules .      poor\n             general condition (serious diseases - infections,cardiovascular or cerebral\n             insufficience, severe IHD)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943396", 
            "org_study_id": "FNHK2013/01", 
            "secondary_id": "IGA-NT14037-4/2013"
        }, 
        "intervention": {
            "arm_group_label": "Rheohemapheresis", 
            "description": "Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.", 
            "intervention_name": "rheohemapheresis", 
            "intervention_type": "Procedure", 
            "other_name": [
                "rheopheresis", 
                "double plasma filtration", 
                "cascade filtration"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "age-related macular degeneration", 
            "AMD", 
            "rheohemapheresis", 
            "plasma filtration", 
            "electroretinography", 
            "ERG", 
            "multifocal ERG", 
            "double plasma filtration"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "contact": {
                "email": "blaham@email.cz", 
                "last_name": "Milan Blaha, Prof, MD", 
                "phone": "00420-495214555"
            }, 
            "facility": {
                "address": {
                    "city": "Hradec Kralove", 
                    "country": "Czech Republic", 
                    "zip": "50005"
                }, 
                "name": "Faculty Hospital"
            }, 
            "investigator": {
                "last_name": "Milan Blaha, Prof MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "Rationalization of the Systemic Treatment of Age-related Macular Degeneration With Rheohemapheresis (RHF)", 
        "overall_contact": {
            "email": "blaham@email.cz", 
            "last_name": "Milan Blaha, Prof,  MD", 
            "phone": "+420495834555"
        }, 
        "overall_official": {
            "affiliation": "Charles University, Medical Faculty and Faculty Hospital, 50005 Hradec Kralove, CZ", 
            "last_name": "Milan Blaha, Prof, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: State Institute for Drug Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of functional   changes in single retinal layers and areas by newest special electrophysiologic methods", 
            "measure": "Electroretinography", 
            "safety_issue": "Yes", 
            "time_frame": "2.5 years"
        }, 
        "reference": [
            {
                "PMID": "15255027", 
                "citation": "Augood C, Fletcher A, Bentham G, Chakravarthy U, de Jong PT, Rahu M, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Vioque J, Young I. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol. 2004 Apr;11(2):117-29."
            }, 
            {
                "PMID": "17309569", 
                "citation": "Bl\u00e1ha M, Cermanov\u00e1 M, Bl\u00e1ha V, Blazek M, Mal\u00fd J, Sirok\u00fd O, Solichov\u00e1 D, Filip S, Reh\u00e1cek V. Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia. Ther Apher Dial. 2007 Feb;11(1):9-15."
            }, 
            {
                "PMID": "20129368", 
                "citation": "Blaha M, Zadak Z, Blaha V, Andrys C, Havel E, Vyroubal P, Blazek M, Filip S, Lanska M, Maly J. Extracorporeal LDL cholesterol elimination (25 years of experience in CZ). Atheroscler Suppl. 2009 Dec 29;10(5):17-20. doi: 10.1016/S1567-5688(09)71804-5."
            }, 
            {
                "PMID": "19559652", 
                "citation": "Borberg H. 26 years of LDL--apheresis: a review of experience. Transfus Apher Sci. 2009 Aug;41(1):49-59. doi: 10.1016/j.transci.2009.05.013. Epub 2009 Jun 25."
            }, 
            {
                "PMID": "17270675", 
                "citation": "Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007 Feb;114(2):253-62."
            }, 
            {
                "PMID": "18724980", 
                "citation": "Friedman E. The pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2008 Sep;146(3):348-9. doi: 10.1016/j.ajo.2008.05.017."
            }, 
            {
                "PMID": "12877897", 
                "citation": "Klingel R, Fassbender C, Fassbender T, G\u00f6hlen B. Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine. Transfus Apher Sci. 2003 Aug;29(1):71-84. Review."
            }, 
            {
                "PMID": "20609179", 
                "citation": "Klingel R, Fassbender C, Heibges A, Koch F, Nasemann J, Engelmann K, Carl T, Meinke M, Erdtracht B. RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration. Ther Apher Dial. 2010 Jun;14(3):276-86. doi: 10.1111/j.1744-9987.2010.00807.x. PubMed PMID: 20609179."
            }, 
            {
                "PMID": "19629514", 
                "citation": "Koss MJ, Kurz P, Tsobanelis T, Lehmacher W, Fassbender C, Klingel R, Koch FH. Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART. Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1297-306. doi: 10.1007/s00417-009-1113-7. Epub 2009 Jul 23."
            }, 
            {
                "PMID": "20102350", 
                "citation": "Rencov\u00e1 E, Bl\u00e1ha M, Studni\u010dka J, Bla\u017eek M, Bl\u00e1ha V, Dusov\u00e1 J, Mal\u00fd J, Kyprianou G, Va\u0161\u00e1tko T, Langrov\u00e1 H. Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form. Acta Ophthalmol. 2011 Aug;89(5):463-71. doi: 10.1111/j.1755-3768.2009.01710.x. Epub 2010 Jan 22."
            }, 
            {
                "PMID": "22304025", 
                "citation": "Troutbeck R, Al-Qureshi S, Guymer RH. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Experiment Ophthalmol. 2012 Jan-Feb;40(1):18-26. doi: 10.1111/j.1442-9071.2011.02581.x. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943396"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Hradec Kralove", 
            "investigator_full_name": "Karel Antos", 
            "investigator_title": "Deputy director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To verify till undescribed changes of complement, some cytokines,factors monitoring endothelial function, and apoptosis  markers, important for rapid repair of retinal revitalization.", 
            "measure": "immunologic parameters changes", 
            "safety_issue": "Yes", 
            "time_frame": "2.5 years"
        }, 
        "source": "University Hospital Hradec Kralove", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital Hradec Kralove", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}